{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:03:43Z","timestamp":1753891423775,"version":"3.41.2"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Dengue annually infects millions of people from a regionally and seasonally varying dengue virus population circulating as four distinct serotypes. Effective protection against dengue infection and disease requires tetravalent vaccine formulations to stimulate a balanced protective immune response to all four serotypes. However, this has been a challenge to achieve, and several clinical trials with different leading vaccine candidates have demonstrated unbalanced replication and interference of interindividual serotype components, leading to low efficacy and enhanced disease severity for dengue-na\u00efve populations. Production of serotype-specific neutralizing antibodies is largely viewed as a correlate of protection against severe dengue disease. However, the underlying mechanisms that lead to these protective immune responses are not clearly elucidated. In this work, using a stochastic model of B cell affinity maturation, we tested different live-attenuated vaccine constructs with varied viral replication rates and contrasted the initiation and progress of adaptive immune responses during tetravalent vaccination and after dengue virus challenge. Comparison of our model simulations across different disease-severity levels suggested that individual production of high levels of serotype-specific antibodies together with a lower cross-reactive antibody are better correlates for protection. Furthermore, evolution of these serotype-specific antibodies was dependent on the percent of viral attenuation in the vaccine, and production of initial B cell and T cell populations pre- and post-secondary dengue infection was crucial in providing protective immunity for dengue-na\u00efve populations. Furthermore, contrasting disease severity with respect to different dengue serotypes, our model simulations showed that tetravalent vaccines fare better against DENV-4 serotype when compared to other serotypes.<\/jats:p>","DOI":"10.3389\/fmolb.2023.1100434","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T02:05:50Z","timestamp":1689386750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs"],"prefix":"10.3389","volume":"10","author":[{"given":"Venkat R.","family":"Pannala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Wallqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: Construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J. Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0005395","DOI":"10.1371\/journal.pntd.0005395","article-title":"Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus","volume":"11","author":"Chaudhury","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.4049\/jimmunol.1401054","article-title":"Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1","volume":"193","author":"Chaudhury","year":"2014","journal-title":"J. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.4161\/21645515.2014.972131","article-title":"Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico","volume":"10","author":"Dayan","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/bsp.2010.0032","article-title":"The dengue threat to the United States","volume":"8","author":"Franco","year":"2010","journal-title":"Biosecur Bioterror"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.physchem.58.032806.104637","article-title":"Stochastic simulation of chemical kinetics","volume":"58","author":"Gillespie","year":"2007","journal-title":"Annu. Rev. Phys. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.00606-08","article-title":"Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus","volume":"82","author":"Gromowski","year":"2008","journal-title":"J. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.virol.2010.06.044","article-title":"Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape","volume":"407","author":"Gromowski","year":"2010","journal-title":"Virology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S830","DOI":"10.1093\/clinids\/11.supplement_4.s830","article-title":"Antibody, macrophages, dengue virus infection, shock, and hemorrhage: A pathogenetic cascade","volume":"11","author":"Halstead","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4269\/ajtmh.1974.23.974","article-title":"Etiologies of the experimental dengues of siler and simmons","volume":"23","author":"Halstead","year":"1974","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/s0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv. Virus Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e147066","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jiw576","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2357","DOI":"10.1371\/journal.pntd.0002357","article-title":"Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year","volume":"7","author":"Montoya","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"696755","DOI":"10.3389\/fimmu.2021.696755","article-title":"Stochastic model of the adaptive immune response predicts disease severity and captures enhanced cross-reactivity in natural dengue infections","volume":"12","author":"Nguyen","year":"2021","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development","volume":"4","author":"Pierson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0065-3527(03)59005-4","article-title":"Antigenic structure of flavivirus proteins","volume":"59","author":"Roehrig","year":"2003","journal-title":"Adv. Virus Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of antibody dynamics and infection histories to evaluate dengue risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S1473-3099(14)70834-5","article-title":"Dengue and dengue vectors in the WHO European region: Past, present, and scenarios for the future","volume":"14","author":"Schaffner","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1006\/jtbi.1997.0495","article-title":"Deriving shape space parameters from immunological data","volume":"189","author":"Smith","year":"1997","journal-title":"J. Theor. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1128\/JVI.01805-15","article-title":"Dengue virus prM-specific human monoclonal antibodies with virus replication-enhancing properties recognize a single immunodominant antigenic site","volume":"90","author":"Smith","year":"2016","journal-title":"J. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMe1413146","article-title":"Preventing dengue-is the possibility now a reality?","volume":"372","author":"Thomas","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1099\/0022-1317-82-8-1885","article-title":"Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: Insight into the neutralization mechanism","volume":"82","author":"Thullier","year":"2001","journal-title":"J. Gen. Virol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cyto.a.22520","article-title":"Lymphocytes subsets reference values in childhood","volume":"87","author":"Tosato","year":"2015","journal-title":"Cytom. A"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1309","DOI":"10.1371\/journal.pntd.0001309","article-title":"Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue","volume":"5","author":"Tricou","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J. Infect. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/v3122374","article-title":"The human antibody response to dengue virus infection","volume":"3","author":"Wahala","year":"2011","journal-title":"Viruses"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0009258","DOI":"10.1371\/journal.pntd.0009258","article-title":"Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)","volume":"15","author":"White","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"12980","DOI":"10.1073\/pnas.1117201109","article-title":"A quantitative quasispecies theory-based model of virus escape mutation under immune selection","volume":"109","author":"Woo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4269\/ajtmh.14-0628","article-title":"Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, Singapore","volume":"92","author":"Yung","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1100434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T02:05:52Z","timestamp":1689386752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1100434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":49,"alternative-id":["10.3389\/fmolb.2023.1100434"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2023.1100434","relation":{},"ISSN":["2296-889X"],"issn-type":[{"type":"electronic","value":"2296-889X"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"article-number":"1100434"}}